Bio-orthogonal drug activation
AssigneeKoninklijke Philips N.V.
InventorsMARC STEFAN ROBILLARD, HENDRICUS MARIE JANSSEN, WOLTER TEN HOEVE, RONNY MATHIEU VERSTEEGEN, RAFFAELLA ROSSIN
Life of this patent
Estimating the term…
Loading patent…
AssigneeKoninklijke Philips N.V.
InventorsMARC STEFAN ROBILLARD, HENDRICUS MARIE JANSSEN, WOLTER TEN HOEVE, RONNY MATHIEU VERSTEEGEN, RAFFAELLA ROSSIN
Estimating the term…
The invention relates to a Prodrug activation method, for therapeutics, wherein use is made of abiotic reactive chemical groups that exhibit bio-orthogonal reactivity towards each other. The invention also relates to a Prodrug kit comprising at least one Prodrug and at least one Activator, wherein the Prodrug comprises a Drug and a first Bio-orthogonal Reactive Group (the Trigger), and wherein the Activator comprises a second Bio-orthogonal Reactive Group. The invention also relates to targeted therapeutics used in the above-mentioned method and kit. The invention particularly pertains to antibody-drug conjugates and to bi- and trispecific antibody derivatives.
A kit for the administration and activation of a Prodrug, the kit comprising a Drug linked, directly or indirectly, to a Trigger moiety, and an Activator for the Trigger moiety, wherein the Trigger moiety comprises a dienophile and the Activator comprises a diene, the dienophile satisfying the following formula (1a):
A kit according to any one of the preceding claims, wherein the activator comprises a diene selected from the dienes, according to formulae (2)-(4):
A kit according to any one of the preceding claims, wherein at least one of the drug DD or the linker LD or the trigger moiety TR comprises a targeting agent TT, preferably an antibody.
A kit according to any one of the preceding claims, wherein the drug is a T-cell engaging antibody construct.
The use of a tetrazine as an activator for the release, in a physiological environment, of a substance linked to a compound satisfying formula (1a).
The use of the inverse electron-demand Diels-Alder reaction between a compound satisfying formula (1a) and a tetrazine as a chemical tool for the release, in a physiological environment, of a substance administered in a chemically bound form, wherein the substance is bound to a compound satisfying formula (1a).
Dependencies are inferred from the claim text.